Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

H. Tamura, M. Ishibashi, T. Yamashita, S. Tanosaki, N. Okuyama, A. Kondo, H. Hyodo, E. Shinya, H. Takahashi, H. Dong, K. Tamada, L. Chen, K. Dan, K. Ogata

Research output: Contribution to journalArticle

Abstract

Tumor-associated B7-H1 molecules inhibit antitumor immunity in some malignancies. We found that B7-H1 expression on patient myeloma cells and human myeloma cell lines (HMCLs) was upregulated by cultivating the cells with autologous stromal cells and the human stromal cell line HS-5. Among major cytokines produced by HS-5 cells, interleukin (IL)-6-induced B7-H1 expression on HMCLs. Moreover, HS-5 cell-mediated B7-H1 expression was downregulated by inhibiting IL-6. B7-H1+ HMCLs were more proliferative and less susceptible to antimyeloma chemotherapy compared with B7-H1-HMCLs. Moreover, the former cells showed higher levels of Bcl-2 and FasL expression than the latter. Finally, B7-H1 molecules on HMCLs induced T-cell apoptosis and anergy of tumor-specific T cells. Consistent with these in vitro observations, patients whose myeloma cells expressed high levels of B7-H1 had higher myeloma cell percentages in the bone marrow (BM) and higher serum lactate dehydrogenase levels compared with other myeloma patients. In addition, B7-H1 expression levels were often upregulated after myeloma patients relapsed or became refractory to therapy. Our data indicate that the BM microenvironment upregulates B7-H1 expression on myeloma cells, which links to the two biological actions of inducing T-cell downregulation and enhancing aggressive myeloma-cell characteristics. Modulating the B7-H1 pathway may be worthwhile in myeloma.

Original languageEnglish (US)
Pages (from-to)464-472
Number of pages9
JournalLeukemia
Volume27
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Stromal Cells
Multiple Myeloma
Bone Marrow
Cell Line
B7 Antigens
T-Lymphocytes
Interleukin-6
Down-Regulation
Neoplasms
L-Lactate Dehydrogenase
Immunity
Up-Regulation
Apoptosis
Cytokines
Drug Therapy
Serum

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Tamura, H., Ishibashi, M., Yamashita, T., Tanosaki, S., Okuyama, N., Kondo, A., ... Ogata, K. (2013). Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia, 27(2), 464-472. https://doi.org/10.1038/leu.2012.213

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. / Tamura, H.; Ishibashi, M.; Yamashita, T.; Tanosaki, S.; Okuyama, N.; Kondo, A.; Hyodo, H.; Shinya, E.; Takahashi, H.; Dong, H.; Tamada, K.; Chen, L.; Dan, K.; Ogata, K.

In: Leukemia, Vol. 27, No. 2, 02.2013, p. 464-472.

Research output: Contribution to journalArticle

Tamura, H, Ishibashi, M, Yamashita, T, Tanosaki, S, Okuyama, N, Kondo, A, Hyodo, H, Shinya, E, Takahashi, H, Dong, H, Tamada, K, Chen, L, Dan, K & Ogata, K 2013, 'Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma', Leukemia, vol. 27, no. 2, pp. 464-472. https://doi.org/10.1038/leu.2012.213
Tamura, H. ; Ishibashi, M. ; Yamashita, T. ; Tanosaki, S. ; Okuyama, N. ; Kondo, A. ; Hyodo, H. ; Shinya, E. ; Takahashi, H. ; Dong, H. ; Tamada, K. ; Chen, L. ; Dan, K. ; Ogata, K. / Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. In: Leukemia. 2013 ; Vol. 27, No. 2. pp. 464-472.
@article{f77a6774eac34a31a76cea371de2110b,
title = "Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma",
abstract = "Tumor-associated B7-H1 molecules inhibit antitumor immunity in some malignancies. We found that B7-H1 expression on patient myeloma cells and human myeloma cell lines (HMCLs) was upregulated by cultivating the cells with autologous stromal cells and the human stromal cell line HS-5. Among major cytokines produced by HS-5 cells, interleukin (IL)-6-induced B7-H1 expression on HMCLs. Moreover, HS-5 cell-mediated B7-H1 expression was downregulated by inhibiting IL-6. B7-H1+ HMCLs were more proliferative and less susceptible to antimyeloma chemotherapy compared with B7-H1-HMCLs. Moreover, the former cells showed higher levels of Bcl-2 and FasL expression than the latter. Finally, B7-H1 molecules on HMCLs induced T-cell apoptosis and anergy of tumor-specific T cells. Consistent with these in vitro observations, patients whose myeloma cells expressed high levels of B7-H1 had higher myeloma cell percentages in the bone marrow (BM) and higher serum lactate dehydrogenase levels compared with other myeloma patients. In addition, B7-H1 expression levels were often upregulated after myeloma patients relapsed or became refractory to therapy. Our data indicate that the BM microenvironment upregulates B7-H1 expression on myeloma cells, which links to the two biological actions of inducing T-cell downregulation and enhancing aggressive myeloma-cell characteristics. Modulating the B7-H1 pathway may be worthwhile in myeloma.",
author = "H. Tamura and M. Ishibashi and T. Yamashita and S. Tanosaki and N. Okuyama and A. Kondo and H. Hyodo and E. Shinya and H. Takahashi and H. Dong and K. Tamada and L. Chen and K. Dan and K. Ogata",
year = "2013",
month = "2",
doi = "10.1038/leu.2012.213",
language = "English (US)",
volume = "27",
pages = "464--472",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

AU - Tamura, H.

AU - Ishibashi, M.

AU - Yamashita, T.

AU - Tanosaki, S.

AU - Okuyama, N.

AU - Kondo, A.

AU - Hyodo, H.

AU - Shinya, E.

AU - Takahashi, H.

AU - Dong, H.

AU - Tamada, K.

AU - Chen, L.

AU - Dan, K.

AU - Ogata, K.

PY - 2013/2

Y1 - 2013/2

N2 - Tumor-associated B7-H1 molecules inhibit antitumor immunity in some malignancies. We found that B7-H1 expression on patient myeloma cells and human myeloma cell lines (HMCLs) was upregulated by cultivating the cells with autologous stromal cells and the human stromal cell line HS-5. Among major cytokines produced by HS-5 cells, interleukin (IL)-6-induced B7-H1 expression on HMCLs. Moreover, HS-5 cell-mediated B7-H1 expression was downregulated by inhibiting IL-6. B7-H1+ HMCLs were more proliferative and less susceptible to antimyeloma chemotherapy compared with B7-H1-HMCLs. Moreover, the former cells showed higher levels of Bcl-2 and FasL expression than the latter. Finally, B7-H1 molecules on HMCLs induced T-cell apoptosis and anergy of tumor-specific T cells. Consistent with these in vitro observations, patients whose myeloma cells expressed high levels of B7-H1 had higher myeloma cell percentages in the bone marrow (BM) and higher serum lactate dehydrogenase levels compared with other myeloma patients. In addition, B7-H1 expression levels were often upregulated after myeloma patients relapsed or became refractory to therapy. Our data indicate that the BM microenvironment upregulates B7-H1 expression on myeloma cells, which links to the two biological actions of inducing T-cell downregulation and enhancing aggressive myeloma-cell characteristics. Modulating the B7-H1 pathway may be worthwhile in myeloma.

AB - Tumor-associated B7-H1 molecules inhibit antitumor immunity in some malignancies. We found that B7-H1 expression on patient myeloma cells and human myeloma cell lines (HMCLs) was upregulated by cultivating the cells with autologous stromal cells and the human stromal cell line HS-5. Among major cytokines produced by HS-5 cells, interleukin (IL)-6-induced B7-H1 expression on HMCLs. Moreover, HS-5 cell-mediated B7-H1 expression was downregulated by inhibiting IL-6. B7-H1+ HMCLs were more proliferative and less susceptible to antimyeloma chemotherapy compared with B7-H1-HMCLs. Moreover, the former cells showed higher levels of Bcl-2 and FasL expression than the latter. Finally, B7-H1 molecules on HMCLs induced T-cell apoptosis and anergy of tumor-specific T cells. Consistent with these in vitro observations, patients whose myeloma cells expressed high levels of B7-H1 had higher myeloma cell percentages in the bone marrow (BM) and higher serum lactate dehydrogenase levels compared with other myeloma patients. In addition, B7-H1 expression levels were often upregulated after myeloma patients relapsed or became refractory to therapy. Our data indicate that the BM microenvironment upregulates B7-H1 expression on myeloma cells, which links to the two biological actions of inducing T-cell downregulation and enhancing aggressive myeloma-cell characteristics. Modulating the B7-H1 pathway may be worthwhile in myeloma.

UR - http://www.scopus.com/inward/record.url?scp=84873569613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873569613&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.213

DO - 10.1038/leu.2012.213

M3 - Article

C2 - 22828443

AN - SCOPUS:84873569613

VL - 27

SP - 464

EP - 472

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -